plerixafor has been researched along with Peripheral Nerve Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, JS; Jin, HK; Kim, BJ; Lee, JK; Schuchman, EH | 1 |
| Cheung, CW; Chung, SK; Luo, X; Qiu, Q; Sun, L; Tai, WL; Xia, Z | 1 |
| Deng, L; Guindon, J; Hohmann, AG; Makriyannis, A; Thakur, GA; Vemuri, VK; White, FA | 1 |
3 other study(ies) available for plerixafor and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Synergistic vasculogenic effects of AMD3100 and stromal-cell-derived factor-1α in vasa nervorum of the sciatic nerve of mice with diabetic peripheral neuropathy.
Topics: Animals; Benzylamines; Chemokine CXCL12; Cyclams; Diabetic Neuropathies; Endothelial Cells; Heterocyclic Compounds; Humans; Mice; Mice, Inbred BALB C; Neovascularization, Physiologic; Peripheral Nervous System Diseases; Receptors, CXCR4; Sciatic Nerve; Stem Cells; Vasa Nervorum | 2013 |
Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.
Topics: Animals; Benzylamines; Blotting, Western; Cyclams; Dose-Response Relationship, Drug; Heterocyclic Compounds; Injections, Spinal; Ligation; Mice; Neuralgia; Peripheral Nervous System Diseases; Receptors, CXCR4; Rotarod Performance Test; Sciatic Nerve; Spinal Cord | 2014 |
The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.
Topics: Animals; Benzylamines; Chromones; Cisplatin; Cryopyrin-Associated Periodic Syndromes; Cyclams; Disease Models, Animal; Heterocyclic Compounds; Hyperalgesia; Indoles; Male; Paclitaxel; Peripheral Nervous System Diseases; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Receptors, CXCR4; Signal Transduction; Time Factors; Treatment Outcome | 2012 |